XLO

Xilio Therapeutics, Inc.

XLO · CIK 1840233 · Annual (10-K) · Last 4 years

Financial Trends

Revenue$6M
20212024
Net Income−$58M
20212024
Operating CF−$18M
20212024
Free Cash Flow−$18M
20212024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕
Revenue$0.0B———
Cost of Revenue————
Gross Profit————
R&D Expense$0.0B$0.1B$0.1B$0.1B
SG&A Expense————
Operating Income$-0.1B$-0.1B$-0.1B$-0.1B
Net Income$-0.1B$-0.1B$-0.1B$-0.1B
EPS (Basic)$-1.09$-2.78$-3.22$-13.52
EPS (Diluted)$-1.09$-2.78$-3.22$-13.52

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕
Total Assets$0.1B$0.1B$0.1B$0.2B
Current Assets$0.1B$0.0B$0.1B$0.2B
Cash & Equivalents$0.1B$0.0B$0.1B$0.2B
Total Liabilities$0.1B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.0B$0.0B$0.1B$0.2B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕
Operating Cash Flow$-0.0B$-0.1B$-0.1B$-0.1B
Investing Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$-0.0B$-0.0B$0.3B
← Companies